Antipsychotic May Fuel Urge to Gamble Antipsychotic May Fuel Urge to Gamble
An updated literature review provides more evidence of an association between gambling disorder and the second-generation atypical antipsychotic aripiprazole.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 15, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news

One-Day Injectable Aripiprazole Tx Passes Test
(MedPage Today) -- Results comparable to traditional 21-day oral regimen (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 8, 2018 Category: Primary Care Source Type: news

The Drugs That Changed Our Minds by Lauren Slater – review
Twenty years after hailing antidepressants in her memoir Prozac Diary, a now jaded, sceptical Lauren Slater revisits the psychopharmacological industry – with uneven resultsInProzac Diary (1998), Lauren Slater wrote powerfully of the way fluoxetine had transformed her previously chaotic life. While the author recorded a handful of negative side-effects – a profound loss of libido, for instance – the reader was left with the sense that Prozac had pieced back together the shards of Slater’s existence. In some ways,The Drugs That Changed Our Minds is a sequel to that book. Slater is now in her mid-50s, recently divorc...
Source: Guardian Unlimited Science - April 1, 2018 Category: Science Authors: Alex Preston Tags: Autobiography and memoir Science and nature Books Medical research Depression Society Culture Source Type: news

Proteus CMO talks regulation hurdles, future plans for digital pill
It ’s still the early days, but the FDA’s approval of Proteus Digital Health and Otsuka Pharmaceuticals’ Abilify MyCite has changed the discussion of digital technology in healthcare. (Source: mobihealthnews)
Source: mobihealthnews - March 8, 2018 Category: Information Technology Source Type: news

Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation) - Ostinelli EG, Jajawi S, Spyridi S, Sayal K, Jayaram MB.
BACKGROUND: People experiencing psychosis may become aggressive. Antipsychotics, such as aripiprazole in intramuscular form, can be used in such situations. OBJECTIVES: To evaluate the effects of intramuscular aripiprazole in the treatment of psych... (Source: SafetyLit)
Source: SafetyLit - January 15, 2018 Category: International Medicine & Public Health Tags: Occupational Issues Source Type: news

Pharma news in clinical trials, chronic condition management, and innovation from Q4 2017
Digital health in pharma definitely had a milestone moment in the fourth quarter with the FDA approval of Abilify MyCite, a new, sensor-enabled version of Otsuka ’s drug for schizophrenia powered by Proteus Digital Health’s ingestible sensor technology. In addition to that, the quarter saw numerous other moves by pharma companies around clinical trials, chronic disease management, mental health, and, more generally, innovation. (Source: mobihealthnews)
Source: mobihealthnews - December 27, 2017 Category: Information Technology Source Type: news

Gene Polymorphisms and Aripiprazole-induced Autonomic Dysfunction Gene Polymorphisms and Aripiprazole-induced Autonomic Dysfunction
Certain polymorphisms in the ABCB1 gene appear to be linked to aripiprazole-induced autonomic nervous system dysfunction in patients with schizophrenia, researchers from Japan report.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - December 20, 2017 Category: Pathology Tags: Psychiatry News Source Type: news

Abilify MyCite (Aripiprazole Tablets with Sensor) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 27, 2017 Category: Drugs & Pharmacology Source Type: news

In-Depth: How digital sensors could change the face of pharma
Earlier this week, Proteus Digital Health and Otsuka Pharmaceuticals announced that Abilify MyCite, a new, sensor-enabled version of Otsuka ’s drug for schizophrenia, had received FDA approval for mental health conditions including schizophrenia and bipolar disorder. (Source: mobihealthnews)
Source: mobihealthnews - November 17, 2017 Category: Information Technology Source Type: news

FDA Approves First Pill with Digital Tracker
The FDA has approved a new version of the antipsychotic aripiprazole embedded with a digital sensor to allow patients to track when the medication was... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 15, 2017 Category: Primary Care Source Type: news

Digital pill could address a "big problem" with medication
CBS News chief medical correspondent Dr. Jon LaPook explains how the digital pill, Abilify MyCite, works (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 15, 2017 Category: Consumer Health News Source Type: news

Otsuka, Proteus finally win FDA approval for sensor-equipped Abilify
The first drug in the US with a digital ingestion tracking system has been approved by the FDA. The pill, Abilify MyCite, is prescribed for treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and as an add-on treatment for depression in adults. (Source: mobihealthnews)
Source: mobihealthnews - November 14, 2017 Category: Information Technology Source Type: news

FDA approves first trackable pill that syncs with a phone
The FDA approved a pill that tracks when patients take their prescribed psychiatric drug. The medication, Abilify MyCite, is a variation on a drug used to treat schizophrenia and bipolar disorder. (Source: the Mail online | Health)
Source: the Mail online | Health - November 14, 2017 Category: Consumer Health News Source Type: news

FDA Clears Drug With Ingestible Digital Tracker FDA Clears Drug With Ingestible Digital Tracker
Abilify MyCite is the first drug approved in the United States that has a digital tracking system for patients and providers to monitor medication intake.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 14, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

'Digital Pill' Lets Doctors Know It's Been Taken
The U.S. Food and Drug Administration has given the nod to Abilify MyCite, for use in patients with schizophrenia, an add-on treatment for depression, and to help control episodes of either manic or "mixed" episodes for people with bipolar disorder. (Source: WebMD Health)
Source: WebMD Health - November 14, 2017 Category: Consumer Health News Source Type: news